This page is used by password-protected to preview the form on customizer
Recent Posts
- The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science
- NImmune Biopharma Acquires Development and Commercialization Rights to Omilancor in Asian Markets
- The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic Control of Systemic Lupus Erythematosus in the Journal of Immunology
- NImmune Biopharma to Participate in UBS Virtual Biotechnology Private Company
- The AI Paradigm Shift: How Cutting-Edge Tech is Fast-Tracking the Future of Medicine
Recent Comments
No comments to show.